Researchers also developed a nanosatellite vaccine targeting a tumour antigen to enhance the efficacy of the STING (interferon gene stimulator) agonist and sensitize SOX2-expressing HNSCCs to checkpoint blockade. The gene discussed is STING1; the disease is neoplasm.